| Symbol | ETON |
|---|---|
| Name | ETON PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21925 WEST FIELD PARKWAY,SUITE 235, DEER PARK, Illinois, 60010-7278, United States |
| Telephone | +1 847 787-7361 |
| Fax | — |
| — | |
| Website | https://www.etonpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001710340 |
| Description | Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development. Additional info from NASDAQ: |
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Read moreEton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Read more(70% Positive) ETON PHARMACEUTICALS, INC. (ETON) Provides Update on treatments for rare diseases
Read moreEton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
Read moreNew Form 4/A - Eton Pharmaceuticals, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001493152-26-033818 <b>Size:</b> 8 KB
Read moreOpaleye Management Inc. 🔴 sold 28.3K shares of Eton Pharmaceuticals, Inc. (ETON) at $37.54 ($1.1M) Transaction Date: Jul 14, 2026 | Filing ID: 033577
Read moreOpaleye Management Inc. 🔴 sold 126.7K shares of Eton Pharmaceuticals, Inc. (ETON) at $38.37 ($4.8M) Transaction Date: Jul 02, 2026 | Filing ID: 032394
Read more📋 Gruber James R. (Officer) plans to sell 25K shares of Eton Pharmaceuticals, Inc. (at $35.01 each, total $875K) Filed: Jun 25, 2026 | ID: 000255
Read more📋 Gruber James R. (Officer) plans to sell 25K shares of Eton Pharmaceuticals, Inc. (at $33.23 each, total $831K) Filed: Jun 23, 2026 | ID: 000254
Read moreDirector Adams Jennifer McKie 🟡 adjusted position in 50.0K shares (1 derivative) of Eton Pharmaceuticals, Inc. (ETON) at $32.48 ($2.0M) Transaction Date: Jun 17, 2026 | Filing ID: 021000
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TRC093 recombinant humanized IgG1k monoclonal antibody | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT00492830 |
| TRC102 + pemetrexed | DRUG | Phase PHASE1 | Neoplasm | COMPLETED | NCT00692159 |
| TRC105 chimeric anti-CD105 antibody | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT00582985 |
| Tiotropium | DRUG | Phase PHASE2 | Asthma | COMPLETED | NCT02382510 |
| Placebo | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02133339 |
| TRN-157 | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02133339 |
| TRC105 and Bevacizumab | DRUG | Phase PHASE1 | Adult Solid Tumor | COMPLETED | NCT01332721 |
| Capecitabine | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT01326481 |
| Bevacizumab | BIOLOGICAL | Phase PHASE2 | Choriocarcinoma | COMPLETED | NCT02396511 |
| Votrient | DRUG | Phase PHASE3 | Advanced Angiosarcoma | COMPLETED | NCT02979899 |
| TRC105 and Pazopanib | DRUG | Phase PHASE1 | Advanced Soft Tissue Sarcoma | COMPLETED | NCT01975519 |
| OPDIVO | DRUG | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT03181308 |
| Sorafenib | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT02560779 |
| Carotuximab (TRC105) | DRUG | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT03181308 |
| Axitinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT01806064 |
| TRC105 and Axitinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT01806064 |
| TRC253 | DRUG | Phase PHASE1 | Metastatic Castrate-resistant Prostate Cancer | COMPLETED | NCT02987829 |
| TRC105 | DRUG | Phase PHASE1 | Metastatic Breast Cancer | COMPLETED | NCT01326481 |
| Atezolizumab | DRUG | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT03835949 |
| TJ004309 | DRUG | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT03835949 |
| Cemiplimab | BIOLOGICAL | Phase PHASE1 | Oncology | COMPLETED | NCT05259696 |
| E-602 | BIOLOGICAL | Phase PHASE1 | Oncology | COMPLETED | NCT05259696 |
| Matching placebo control | DRUG | Phase PHASE2 | Uncontrolled Hypertension | RECRUITING | NCT07142356 |
| RTN-001 | DRUG | Phase PHASE2 | Uncontrolled Hypertension | RECRUITING | NCT07142356 |